Navigation Links
Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug

PT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELASE. Forward looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Pacgen's current beliefs as well as assumptions made by and information currently available to Pacgen and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Pacgen in its Final Prospectus dated November 28, 2006, actual events may differ materially from current expectations. Pacgen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For all forward-looking statements, Pacgen claims the safe harbour for forward-looking statements within the meaning of the Private Securities Legislation Reform.

    TELECONFERENCE CALL NOTIFICATION: Monday, May 7, 2007 4:30pm EDT/

    -----------------------------------------------------------------

    1:30pm PDT

    ----------

On May 7, 2007, Pacgen Biopharmaceuticals Corp. will host a teleconference call at 4:30pm EDT (1:30pm PDT). To participants in the teleconference call please dial 1-800-589-8577 in Canada and the U.S. or 00-800-0022-8228 Internationally before 4:30pm EDT. The reservation number required for access is # 21231386. This
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/23/2014)... ROCHESTER, N.Y. , July 23, 2014 ... VSCP ), a leading provider of clinical trial ... , 48, has been named president and chief executive ... of Directors in August 2013 and has held the ... October 25, 2013. Dr. Charles E. ...
(Date:7/23/2014)... , July 23, 2014 Research ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & by ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is segmented into three major segments, namely, holter monitor, ... market was valued at $3,683 million in 2013 and ...
(Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3
... 16, 2012 /PRNewswire-iReach/ -- Chronic pain is ... causes of persistent, debilitating back pain. Chicago resident Pedro ... livelihood and soured his outlook on life. After taking ... he finally found relief with non-surgical treatment at the ...
...  Rubicon Genomics, Inc., a leader in the development ... the performance and capabilities of DNA and RNA ... announced the launch of the first product in ... designed and optimized for next generation sequencing (NGS).  ...
Cached Medicine Technology:The Illinois Back Institute Helps Patient Beat Debilitating Back Pain 2Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications 2Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications 3
(Date:7/23/2014)... (PRWEB) July 23, 2014 “Unlike most ... focus on developing your own unique gifts, talents and ... and clichéd sales verbiage, “says Ja Marr Brown. ... Sales Story?" which chronicles Brown’s transformation from nearly getting ... of The Year, winning every sales contest offered and ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The ... ratified today a robust trial for a defined ... of risk adjusting relevant quality measures for sociodemographic ... NQF policy.     , Sociodemographic factors can be socioeconomic, ... race, ethnicity, and primary language. Growing evidence ...
(Date:7/23/2014)... 23, 2014 In preparation for National ... Millennium Treatment Group is providing tips on choosing a ... society ever since man first figured out the process ... has existed since shortly thereafter. Its basis lies in ... then developing a way to combat that problem while ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, ... overweight American children and teens look in the mirror ... officials reported Wednesday. "Being overweight or obese is ... pressure, high cholesterol and diabetes," said lead researcher Neda ... Disease Control and Prevention,s National Center for Health Statistics. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Inventor and ... From football games to the gas pump – sharing ... on Wednesday, July 30 at Noon. , With 24 ... has more patents than anyone in the General Assembly ... superimposed yellow line yard marker as seen on television, ...
Breaking Medicine News(10 mins):Health News:Using Your Story and Not Technique to Achieve Sales Success 2Health News:NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Celebrating Innovation and Invention 2
... synthetic bone matrix offers hope for babies born with craniosynostosis, ... fuse too soon. Implants replacing some of the infant,s bone ... currently used to treat the condition. "The remarkable thing ... matrix changes what the cells around it do. Cells begin ...
... disease, stroke more likely for organ recipients with sleep ... News) -- Kidney transplant patients with sleep apnea are ... and stroke, Hungarian researchers say. , The study of ... moderate to severe sleep apnea, a rate similar to ...
... and costs, study finds , THURSDAY, Nov. 19 (HealthDay ... angiography is quicker, more accurate and much less expensive ... to moderate enzyme and EKG scores, according to a ... pain patients at 16 emergency rooms who were randomly ...
... 19 2009 has been a monumental year for ... from QUITPLAN Services, QuitCash Challenge, helped the 31-year-old Columbia ... The Challenge. Nearly 2,000 Minnesotans, including Doug, attempted to ... win the $5,000 grand prize. , On Thursday, November ...
... Official Statement by Teamsters General President Jim Hoffa ... Jim Hoffa issued the following statement today about the Senate ... health plans that will mean a huge middle-class tax hike ... would impose an excise tax on insurers for higher-cost health ...
... Nov. 19 Monogram Energy, Inc. ("Monogram") (Pink Sheets: ... of Triad Therapeutics, Inc. ("Triad"), which was effective as ... the Stock Purchase and Recapitalization Agreement, shareholders of Monogram ... exchange for approximately 95% ownership to the Triad shareholders ...
Cached Medicine News:Health News:Bone implant offers hope for skull deformities 2Health News:Kidney Transplant, Sleep Disorder May Add Up to Trouble 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 3Health News:Monogram Energy, Inc. Acquires Triad Therapeutics, Inc. 2
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: